These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25743674)

  • 1. [New freedoms in insulin therapy].
    MMW Fortschr Med; 2015 Feb; 157(3):64. PubMed ID: 25743674
    [No Abstract]   [Full Text] [Related]  

  • 2. [New flexibility in diabetes therapy].
    Danne T
    MMW Fortschr Med; 2015 Feb; 157(3):65. PubMed ID: 25743681
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-acting basal insulin].
    Meißner T
    MMW Fortschr Med; 2015 Jul; 157(13):82. PubMed ID: 26206056
    [No Abstract]   [Full Text] [Related]  

  • 4. [New formulation with improved pharmacokinetics].
    Walter M
    MMW Fortschr Med; 2015 Feb; 157(3):69. PubMed ID: 25743680
    [No Abstract]   [Full Text] [Related]  

  • 5. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25417447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term use of intravenous insulin because of failure of subcutaneous insulin treatment.
    Diaz-Pereda L; Yang TI; Knowles HC
    Trans Am Clin Climatol Assoc; 1979; 90():102-8. PubMed ID: 516224
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new long-acting insulin analog. "Fewer hypoglycemias observed"].
    Gallwitz B
    MMW Fortschr Med; 2004 Jan; 146(3-4):47. PubMed ID: 15035450
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypoglycemia rates with basal insulin analogs.
    Little S; Shaw J; Home P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S53-64. PubMed ID: 21668338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes].
    Gallwitz B; Haak T
    MMW Fortschr Med; 2013 Oct; 155 Suppl 3():76-82. PubMed ID: 24930317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.
    Kobuke K; Yoneda M; Nakanishi S; Ohno H; Maeda S; Egusa G
    J Diabetes Investig; 2016 Jan; 7(1):94-9. PubMed ID: 26816606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of subcutaneous insulin management protocols and order sets in inpatient diabetes management.
    Houlden RL; Moore S; Cornish W; Tiwana K
    Can J Diabetes; 2014 Apr; 38(2):101-17. PubMed ID: 24690505
    [No Abstract]   [Full Text] [Related]  

  • 12. [Insulin therapy with pens and pumps].
    Schwedes U
    Med Klin (Munich); 1996 Feb; 91 Suppl 1():16. PubMed ID: 8839106
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetes experts evaluate therapy with modern insulin analogs positively (interview by Dr. Silke Wedekind)].
    Renner R; Lundershausen R
    MMW Fortschr Med; 2013 May; 155(9):66-7. PubMed ID: 23951666
    [No Abstract]   [Full Text] [Related]  

  • 14. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
    Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
    Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
    [No Abstract]   [Full Text] [Related]  

  • 15. [Injection time flexibility when needed].
    Pickl S
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():87. PubMed ID: 26012997
    [No Abstract]   [Full Text] [Related]  

  • 16. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials.
    Hollander PA; Krasner A; Klioze S; Schwartz P; Duggan W
    Diabetes Care; 2007 Oct; 30(10):2508-10. PubMed ID: 17536080
    [No Abstract]   [Full Text] [Related]  

  • 18. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating to target in type 2 diabetes: the BEGIN trial programme.
    Wangnoo SK; Chowdhury S; Rao PV
    J Assoc Physicians India; 2014 Jan; 62(1 Suppl):21-6. PubMed ID: 25330628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin Glargine U-300 (Toujeo®): A Review.
    Grant JS; Graven LJ
    Home Healthc Now; 2016 Mar; 34(3):156-7. PubMed ID: 26925942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.